Objectives: To assess the value of 18FDG PET/CT in stage diagnosis in esophageal cancer patients. Subjects and methods: 32 esophageal cancer patients were performed 18FDG PET/CT for initial stage diagnosis before the treatment. | Journal of military pharmaco-medicine no1-2019 18 FDG UPTAKE AND THE VALUE OF PET/CT IN STAGE DIAGNOSIS IN ESOPHAGEAL CANCER PATIENTS Nguyen Van Ba1; Tran Viet Tien1 Pham Ngoc Diep1; Nguyen Danh Thanh1 SUMMARY 18 Objectives: To assess the value of FDG PET/CT in stage diagnosis in esophageal cancer 18 patients. Subjects and methods: 32 esophageal cancer patients were performed FDG PET/CT 18 for initial stage diagnosis before the treatment. Results: FDG uptake of osephageal tumors increased, SUVmax increase from to ; average value ± ; It increased with 18 invasive degree and stage of tumor. The FDG PET/CT changed diagnosis of T stage in 2/32 patients (), of N stage in 15/32 patients (), detected metastases in 14 patients. 18 After using FDG PET/CT, 14/32 patients () were upstaged, which included 7/10 patients 18 (70%) of stage I and II and 7/15 patients () of stage III. Conclusion: FDG PET/CT scan effectively detected nodes, distant metastases, it had great value in stage diagnosis of esophageal cancer patients. * Keywords: Esophageal cancer; Staging diagnosis; INTRODUCTION Esophageal cancer ranks sixth in men, ninth in women in the world. The percentage of men and women varies from 4:1 to 14:1 or higher. According to the World Cancer Research Association, there are about 482,000 new cancer cases each year, of which the mortality rate is very high, 84% of esophageal cancer cases died in 2008. For effective treatment of esophageal cancer, accurate diagnosis of the stage is very important. The main advantage of 18 FDG PET/CT scan is localizing nodal lesions, nodal metastases, mediastinal lymph nodes, and lymph node metastasis are identified with high sensitivity and specificity. 18FDG PET/CT allows for more accurate detection of distant metastatic 18 FDG PET/CT. lesions such as lung metastases, liver metastases, bone metastases that other conventional tests have not yet screened. Thus, based on new lesions detected on 18 FDG .
